-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $172

Benzinga·05/07/2025 17:19:16
Listen to the news
RBC Capital analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and lowers the price target from $182 to $172.